ONX-0914 (PR-957)

Catalog No.S7172

For research use only.

ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

ONX-0914 (PR-957) Chemical Structure

CAS No. 960374-59-8

Selleck's ONX-0914 (PR-957) has been cited by 14 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Other Proteasome Products

Biological Activity

Description ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.
Features The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).
Targets
LMP7 [1]
(Cell-free assay)
~10 nM
In vitro

ONX-0914 is 20- to 40-fold more selective for LMP7 over the next most sensitive sites, β5 or LMP2. ONX-0914 blocks presentation of LMP7-specific, MHC-I–restricted antigens in vitro and in vivo with minimal cross-reactivity for the constitutive proteasome. Selective inhibition of LMP7 by ONX-0914 blocks production of interleukin-23 (IL-23) by activated monocytes and interferon-gamma and IL-2 by T cells. LMP7 inhibition blocks production of IL-23 by ~90% and of tumor necrosis factor-α (TNF-α) and IL-6 by ~50%.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji NH;xPJFHfW6ldHnvckBie3OjeR?= M1rSb2lvcGmkaYTpc44hd2ZicILveIVie2:vZTDzeYJ2dmm2IHLleIEuPWliaX6gbJVu[W5iUnHqbUBk\WyuczD1d4lv\yCET1TJVHkuVkNyMEWgZpkh\my3b4Lld4NmdnRiZHXud4l1d22ndIL5MEBKSzVyPUCuNFA2P87:TR?= NXz2[GhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFY4PDZpPkK1NFA3PzR4PD;hQi=>
EBC1 NVv4e5NKSW62aYT1cY9zKGG|c3H5 NWW0dmx4OTVibXevb4c> NGDxWZU2KGSjeYO= NFjyOpJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIFPEMVEhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiC{ZXfy[ZN{cW:wIHH0JFE2KG2pL3vnMEBxdyCzZDDh[I1qdmm|dHXy[YQh\m:{IEWg[IF6eyCxbjDhcoQhOiCmYYnzJI9n\iC3cDD0c{A{OiCmYYnz NFX1bHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOlc1Pid-MkWwNFY4PDZ:L3G+
SJ-GBM2 Mnr3dWhVWyCjc4PhfS=> NYDtU5FUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> NH30N2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOlc1Pid-MkWwNFY4PDZ:L3G+
SK-N-SH NEnMZ2JyUFSVIHHzd4F6 MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NF;vRZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOlc1Pid-MkWwNFY4PDZ:L3G+
RPMI8226 M1m1UmZ2dmO2aX;uJIF{e2G7 NXHvPIFIUW6qaXLpeIlwdiCxZjDwdo91\WG|b33lJJN2[nWwaYSgZoV1[S1zaTDpckBpfW2jbjDSVG1KQDJ{NjDj[YxteyC3c3nu[{BDV0SLUGmtUmMxODFiYomg[ox2d3Knc3PlcpQh\GWwc3n0c41mfHK7LDDJR|UxRTBwM{VOwG0> M4PvcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC2O|Q3Lz5{NUCwOlc1PjxxYU6=
Raji Ml\aSpVv[3Srb36gZZN{[Xl? NV3vR3J3UW6qaXLpeIlwdiCxZjDwdo91\WG|b33lJJN2[nWwaYSgZoV1[S1zaTDpckBpfW2jbjDSZYpqKGOnbHzzJJV{cW6pIFLPSGlRYS1iZYDvfI9ucWOrbjDifUBndHWxcnXzZ4VvfCCmZX7zbZRwdWW2comsJGlEPTB;MD60Ou69VQ>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNke0Okc,OjVyME[3OFY9N2F-
Raji NYrEfVNxTnWwY4Tpc44h[XO|YYm= MlviTY5pcWKrdHnvckBw\iCycn;0[YF{d22nIIP1ZpVvcXRiYnX0ZU0zcSCrbjDoeY1idiCUYXrpJINmdGy|IIXzbY5oKEKRRFnQXU0h\XCxeH;tbYNqdiCkeTDmcJVwemW|Y3XueEBl\W6|aYTvcYV1enluIFnDOVA:OC53Od88US=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNke0Okc,OjVyME[3OFY9N2F-
RPMI8226 NHjFdW5HfW6ldHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKHC{b4TlZZNwdWVic4XieY5qfCCkZYThMVJqKGmwIHj1cYFvKFKSTVm4NlI3KGOnbHzzJJV{cW6pIFLPSGlRYS2ncH;4c41q[2mwIHL5JIZtfW:{ZYPj[Y51KGSnboPpeI9u\XS{eTygTWM2OD1yLkW5{txO NFT1ZW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOlc1Pid-MkWwNFY4PDZ:L3G+
Raji Mn\LSpVv[3Srb36gZZN{[Xl? M{XpTGlvcGmkaYTpc44hd2ZiMkDzJJBzd3SnYYPvcYUhe3WkdX7peEBj\XSjLULjJIlvKGi3bXHuJHJicmliY3XscJMhfXOrbnegRm9FUVC\LTDldI95d22rY3nuJIJ6KG[udX;y[ZNk\W62IHTlcpNqfG:vZYTyfUwhUUN3ME2xMlHPxE1? NYLoenVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFY4PDZpPkK1NFA3PzR4PD;hQi=>
RPMI8226 MUnGeY5kfGmxbjDhd5NigQ>? MlnwTY5pcWKrdHnvckBw\iB{MIOgdJJwfGWjc3;t[UB{fWK3bnn0JIJmfGFvMnOgbY4hcHWvYX6gVnBOUTh{Mk[gZ4VtdHNidYPpcochSk:GSWDZMYVxd3ixbXnjbY4h[nliZnz1c5Jme2OnboSg[IVve2m2b33leJJ6NCCLQ{WwQVEvOc7:TR?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNke0Okc,OjVyME[3OFY9N2F-
SK-N-MC M{PKepFJXFNiYYPzZZk> MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN|OUK1Nkc,Ojl|M{myOVI9N2F-
RD M4XzS5FJXFNiYYPzZZk> MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M3LPd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{O5NlUzLz5{OUOzPVI2OjxxYU6=
MG 63 (6-TG R) NEjyOHVyUFSVIHHzd4F6 M4K2eZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN|OUK1Nkc,Ojl|M{myOVI9N2F-
NCI-H727 MUHDfZRwfG:6aXPpeJkh[XO|YYm= NWLSTVkzPDhiaILz MoXoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh5MkegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDIc4VkcHO2IEOzN|QzKHO2YXnubY5oKGKjc3XkJGhEWyCjc4PhfUwhTUN3ME2wMlPPxE1? Mnf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl|M{myOVIoRjJ7M{O5NlUzRC:jPh?=
PC3 MmTjR5l1d3SxeHnjbZR6KGG|c3H5 NEe4ZZI1QCCqcoO= MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBJd2WlaIP0JFM{OzR{IIP0ZYlvcW6pIHLhd4VlKEiFUzDhd5NigSxiRVO1NF0xNjN|zszN MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN|OUK1Nkc,Ojl|M{myOVI9N2F-
HuH7 M2O5ZWN6fG:2b4jpZ4l1gSCjc4PhfS=> NIK5N|E1QCCqcoO= Mnn4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJVJPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KEixZXPod5QhOzN|NEKgd5RicW6rbnegZoF{\WRiSFPTJIF{e2G7LDDFR|UxRTBwM{pOwG0> NYjZPIlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzN|kzPTJpPkK5N|M6OjV{PD;hQi=>
Caco2 NHT3[mFEgXSxdH;4bYNqfHliYYPzZZk> NIrmbW41QCCqcoO= NFr4XXNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[WOxMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFjv[YNpe3RiM{OzOFIhe3SjaX7pcoch[mG|ZXSgTGNUKGG|c3H5MEBGSzVyPUGuN:69VQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN|OUK1Nkc,Ojl|M{myOVI9N2F-
DAOY NIDPRZFyUFSVIHHzd4F6 MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NYTxbGljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzPFA5PjNpPkOwN|gxQDZ|PD;hQi=>
A673 MUDxTHRUKGG|c3H5 MlOzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? NFXaN5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO4NFg3Oyd-M{CzPFA5PjN:L3G+
Rh41 NHzkeY9yUFSVIHHzd4F6 MmPqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NX20PHJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzPFA5PjNpPkOwN|gxQDZ|PD;hQi=>
A20 NVHRUWs2TnWwY4Tpc44h[XO|YYm= M37ZOmlvcGmkaYTpc44hd2ZiTF3QNkBqdiCvb4Xz[UBCOjBiY3XscJMh[nliRVzJV2EtKEmFNUC9NE4{OjkQvF2= NIHGXmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO4NFg3Oyd-M{CzPFA5PjN:L3G+
A20 MnvBSpVv[3Srb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKDJyUzDwdo91\W:|b33lJIJmfGFiNTDpckBud3W|ZTDBNlAh[2WubIOgZpkhTUyLU1GsJGlEPTB;MD60NFHPxE1? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN6MEi2N{c,OzB|OEC4OlM9N2F-
MOLT4 Ml3DSpVv[3Srb36gZZN{[Xl? M3XkSmlvcGmkaYTpc44hd2ZiMkDTJJBzd3Snb4PvcYUh[mW2YTC1JIlvKGi3bXHuJG1QVFR2IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvPDJ{zszN NEWyV|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO4NFg3Oyd-M{CzPFA5PjN:L3G+
A20 NF;NXGRHfW6ldHnvckBie3OjeR?= NGjS[WZKdmirYnn0bY9vKG:oIF3FR2wyKGmwIH3veZNmKEF{MDDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjZ7Od88US=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN6MEi2N{c,OzB|OEC4OlM9N2F-
MOLT4 MWnGeY5kfGmxbjDhd5NigQ>? Mn3kTY5pcWKrdHnvckBw\iCPRVPMNUBqdiCqdX3hckBOV0yWNDDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjlyMt88US=> NIjRN4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO4NFg3Oyd-M{CzPFA5PjN:L3G+
A20 M2OyW2Z2dmO2aX;uJIF{e2G7 NI\TN29KdmirYnn0bY9vKG:oIEKwV{Bxem:2ZX;zc41mKGKndHGgNkBqdiCvb4Xz[UBCOjBiY3XscJMh[nliRVzJV2EtKEmFNUC9NE46OTQQvF2= MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|OEC4OlMoRjNyM{iwPFY{RC:jPh?=
MOLT4 NXPlXINoTnWwY4Tpc44h[XO|YYm= NVK0PJNVUW6qaXLpeIlwdiCxZjCyNHMheHKxdHXvd49u\SCkZYThJFIhcW5iaIXtZY4hVU:OVESgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC57MkhOwG0> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN6MEi2N{c,OzB|OEC4OlM9N2F-
PBMC Mn;HSpVv[3Srb36gZZN{[Xl? NWfwW3I3OTByIH7N MoLEN{B1dyB5MjDodpM> MXTJcohq[mm2aX;uJI9nKDJyUzDwdo91\WG|b33lJIJmfGFiNXmgbY4hcHWvYX6gVGJOSyClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gVHNOSjViZYjwdoV{e2mxbjDheEAyODBibl2gZYZ1\XJiMzD0c{A4OiCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nz NUDQTGNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyPFMzOjJpPkOxNlg{OjJ{PD;hQi=>
PBMC NEm3ZZRHfW6ldHnvckBie3OjeR?= MY[xNFAhdk1? M{D5blMhfG9iN{KgbJJ{ NVfoNo5FUW6qaXLpeIlwdiCxZjCyNHMheHKxdHXhd49u\SCkZYThJFVqKGmwIHj1cYFvKFCETVOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKFCVTVK2JIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFMhfG9iN{KgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTJ6M{KyNkc,OzF{OEOyNlI9N2F-
PBMC NEjEW5NHfW6ldHnvckBie3OjeR?= M3GyOFExOCCwTR?= NVr1O5ZROyC2bzC3NkBpenN? NULtfWN3UW6qaXLpeIlwdiCxZjCyNHMheHKxdHXhd49u\SCkZYThJFVqKGmwIHj1cYFvKFCETVOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKFCVTVK3JIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFMhfG9iN{KgbJJ{KGK7IGLUMXBEWiCvZYToc4Q> NWHzWolsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyPFMzOjJpPkOxNlg{OjJ{PD;hQi=>
In vivo In mouse models of rheumatoid arthritis and lupus, ONX-0914 treatment reverses signs of disease and results in reductions in cellular infiltration, cytokine production and autoantibody levels at well-tolerated doses. The maximum tolerated dose (MTD) of ONX-0914 in mice to be 30 mg/kg body weight. IFN-g release is inhibited by ~60% at LMP7-selective concentrations of ONX-0914 and by ~90% at higher concentrations. Production of IL-2 is also inhibited by ~50%.[1]

Protocol (from reference)

Animal Research:[1]
  • Animal Models: collagen antibody–induced arthritis (CAIA) and collagen-induced arthritis (CIA)
  • Dosages: 2, 6 or 10 mg/kg
  • Administration: i.v.

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(172.21 mM)
Ethanol 100 mg/mL
(172.21 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+castor oil
For best results, use promptly after mixing.

10 mg/mL

Chemical Information

Molecular Weight 580.67
Formula

C31H40N4O7

CAS No. 960374-59-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C(=O)NC(CC1=CC=C(C=C1)OC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C)NC(=O)CN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy ONX-0914 (PR-957) | ONX-0914 (PR-957) supplier | purchase ONX-0914 (PR-957) | ONX-0914 (PR-957) cost | ONX-0914 (PR-957) manufacturer | order ONX-0914 (PR-957) | ONX-0914 (PR-957) distributor